Preferred Label : NKp46/CD16-based BCMA-targeted NK Cell Engager SAR445514;
NCIt synonyms : BCMA-targeting NK Cell Engager SAR445514; NKp46/CD16-based BCMA-targeted NK Cell Engager IPH6401; Anti-BCMA NKp46xCD16 NK Cell Engager SAR445514;
NCIt definition : An engineered tri-specific natural killer (NK) cell engager (NKCE) containing specific
antibodies targeting the tumor-associated antigen (TAA) B-cell maturation antigen
(BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), and the NK
activating receptors natural cytotoxicity triggering receptor (NKp46; activating natural
killer receptor p46) and CD16, with potential immunostimulating and antineoplastic
activities. Upon administration of NKp46/CD16-based BCMA-targeted NK cell engager
SAR445514, the NKCE targets and binds to BCMA expressed on tumor cells and simultaneously
binds, via the activating receptors NKp46 and CD16, to NK cells, thereby bringing
BCMA-expressing tumor cells and NK cells together. This stimulates the NK cells and
results in the selective NK cell-mediated tumor cell lysis of BCMA-expressing tumor
cells. BCMA, a tumor-specific antigen and a member of the tumor necrosis factor receptor
superfamily (TNFRSF) that binds to both a proliferation-inducing ligand (APRIL; TNFSF13)
and B-cell activating factor (BAFF; TNFSF13B), plays a key role in plasma cell survival.
BCMA is found on the surfaces of plasma cells and is overexpressed on malignant plasma
cells.;
Molecule name : SAR-445514; IPH 6401; SAR 445514; IPH-6401;
NCI Metathesaurus CUI : CL1907550;
Origin ID : C200560;
concept_is_in_subset
- has_target
